Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Cemiplimab After CRT in HNSCC
NCT04831450Phase 2Withdrawn
- Sponsor
- University of Miami
- Start
- Jul 2022
- Primary completion
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
01
Overview
A Phase 2 trial of cemiplimab in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Miami. Planned start Jul 2022; status: withdrawn.
02
Drugs
cemiplimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04831450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04831450.